生物试剂
>
生化试剂
>
信号通路
> 洛草氨酸
加入收藏 取消收藏

洛草氨酸  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 10mg 25mg 100mg in glass bottle
溶解性：溶于DMSO（50mg/mL 超声）
产品描述：基本信息 产品编号： L10456 产品名称： Lodoxamide CAS: 53882-12-5   储存条件 粉末 -20℃ 四年     分子式： C11H6ClN3O6 溶于液体 -80℃ 6个月 分子量： 311.63 -20℃ 1个月 化学名：  2,2'-((2-Chloro-5-cyano-1,3-phenylene)bis(azanediyl))bis(2-oxoacetic acid) Solubility (25°C)：   体外:   DMSO   Ethanol   Water   体内(现配现用):   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 3.2089mL 16.0447mL 32.0893mL 5mM 0.6418mL 3.2089mL 6.4179mL 10mM 0.3209mL 1.6045mL 3.2089mL   生物活性 产品描述 作为肥大细胞稳定剂的抗过敏化合物,用于研究哮喘和过敏性结膜炎。 靶点 Histamine Receptor   体外研究 Lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells.The chemotactic response of eosinophils to fMLP as well as to IL-5 is significant and dose-dependent inhibited by Lodoxamide.Lodoxamide is also able to strongly inhibit the release of eosinophil peroxidase after IgA-dependent activation and,to a lesser extent,the release of eosinophil cationic protein and eosinophil-derived neurotoxin. 体内研究 Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys.When given intravenously,orally,or intrabronchially by aerosol,lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized.anesthetized rhesus monkeys.Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation,decreased microvascular permeability,and increased compliance.Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty,cough,sputum production,and sleep.
保存条件：-20℃

猜你喜欢